Neupulse, the brand of Neurotherapeutics Ltd., has secured $3.0 million in a recent funding round. The company specializes in developing non-drug treatments for tic disorders, focusing on innovative neurostimulation techniques. This investment marks a significant step for Neupulse as it advances its mission to provide effective and accessible solutions for individuals managing tic disorders.
The core of Neupulse's technology involves delivering rhythmic patterns of mild electrical stimulation to the median nerve at the wrist. This method has been shown to increase the power and synchronicity of brain oscillations associated with movement suppression, leading to a dramatic reduction in tic frequency and the urge-to-tic. The company's research direction was heavily influenced by feedback from individuals with tic disorders and their families, who expressed a need for a safe, effective, non-drug treatment usable outside of a clinical setting, offering greater control over their condition.
Importantly, Neupulse's research indicates that this type of stimulation does not materially affect volitional movements or impair cognitive functions such as attention. The newly raised capital will be instrumental in supporting Neupulse's growth initiatives. The company plans to allocate these funds towards further research and development, potentially expanding clinical validation efforts, and scaling its operational capabilities to bring its therapeutic approach to a wider audience.
This funding round underscores investor confidence in Neupulse's innovative approach to neurological health. The company is poised to continue its development trajectory, aiming to offer a novel and empowering treatment option for individuals with tic disorders, thereby enhancing their quality of life through accessible, non-pharmacological interventions.
